Free preview
LAQ Comprehensive
MD Pharmacology NMC syllabus Full notes Recent advances last updated on 2026-06-29

Potassium-Sparing Diuretics

Mineralocorticoid-Receptor Antagonists & Epithelial-Na⁺-Channel Blockers — Collecting-Duct Pharmacology, Combination Rationale & Hyperkalaemia Risk

Past RGUHS + MPMSU + MUHS · 7 MUHSSummer '22 MPMSUJul '20 RGUHSNov '17 MPMSU2013 RGUHSMay '09 RGUHSMay '09 RGUHSOct '08

Potassium-Sparing Diuretics

1. Definition, scope & place in the diuretic family

  • Potassium-sparing diuretics are agents that act on the late distal tubule (late DCT) and collecting duct (CD) to produce a mild natriuresis while conserving K+ (and H+) — the opposite of the kaliuresis caused by all more proximally acting diuretics (G&G 14e Ch.29; KDT 8e Ch.42, pp.634–6).
  • Two mechanistically distinct sub-classes are pooled under this label because they share the net urinary-electrolyte signature (↑Na+, ↓K+, ↑Cl-, slight ↑HCO3-, urine mildly alkalinised) (KDT 8e Ch.42, p.636; G&G 14e Ch.29 Table 29-6/29-7):
    • (a) Antagonists of the mineralocorticoid receptor (MR) — "aldosterone antagonists": spironolactone, eplerenone, finerenone (and, outside the U.S./India, canrenone and potassium canrenoate).
    • (b) Inhibitors of the renal epithelial Na+ channel (ENaC) — "Na+ channel blockers": amiloride, triamterene.
  • They are low-efficacy (weak) diuretics: maximal fractional Na+ excretion ≈ 2–3 % of the filtered load, because >90 % of filtered Na+ is already reabsorbed upstream of their site of action (KDT 8e Ch.42, p.624 & Table 42.2, p.637; G&G 14e Ch.29).
  • Consequently they are rarely used as sole agents; their principal roles are (i) to offset the K+ (and Mg2+) loss of loop/thiazide diuretics, (ii) to add a small natriuretic/antihypertensive increment, and (iii) MR antagonists specifically — to deliver disease-modifying benefit in heart failure, primary aldosteronism, cirrhotic ascites and diabetic CKD (G&G 14e Ch.29; KDT 8e Ch.42, pp.634–6).
  • Historical note: spironolactone (aldosterone antagonist) and the ENaC blockers triamterene/amiloride were developed in parallel with the thiazides and loop diuretics in the late 1950s–1960s, expressly to counter diuretic-induced hypokalaemia (KDT 8e Ch.42, p.625).

Comparative urinary-electrolyte signature and efficacy (KDT 8e Ch.42 Table 42.2, p.637)

  • Spironolactone — Na+ ↑, K+ ↓, Cl- ↑, HCO3- –/↑; max ~3 % filtered Na+ excreted; efficacy Low.
  • Amiloride — Na+ ↑, K+ ↓, Cl- ↑, HCO3- –/↑; max ~3 % filtered Na+ excreted; efficacy Low.
  • (Contrast: furosemide 25 % / High; thiazide 8 % / Intermediate; acetazolamide 5 % / Mild.)
Continue reading

Potassium Sparing Diuretics

PharmaNotes Pro · Comprehensive

Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.